BTG3 and systemic lupus erythematosus: Although differences in ANA titer or autoantibody specificity accumulation were not noted with the presence of type 2 symptoms (data not shown), except for sleep disturbances, where no patterns of immune mediator changes were found, there was a consistent increase in plasma BLyS levels, particularly among lupus relatives reporting type 2 symptoms who remained clinically unaffected or only developed ILE.